iBio

Monoclonal antibodies
#iBio #Monoclonal antibodies #Phase I trial #Weight loss

iBio initiates Phase I trial for weight loss antibody

iBio has received approval to initiate a first-in-human clinical trial for its long-acting monoclonal antibody IBIO-600 in Australia.  The Phase I study is a randomised, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight and obese adult… Read More

#News

Monoclonal antibody
#Antibody #iBio #Obesity #Preclinical development #Weight loss

Twice-yearly antibody shows strong therapeutic potential for weight-loss

iBio has announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data.  The findings will be presented during an oral session at ObesityWeek 2025, taking place 4-7 November in Atlanta, USA. … Read More

#News #Trending News